Company intelligence / Profile preview
Blue Earth Therapeutics
Oxford, United Kingdomblueearththerapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company recently completed a Phase 1 clinical trial for its lead candidates and has initiated a Phase 2 clinical trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 injection in metastatic castrate-resistant prostate cancer. First results from the Phase 2 study could be available as soon as H1 2026[6].
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsRadioligand Therapies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
University College London (UCL)
Beyond the preview
Go deeper on Blue Earth Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blue Earth Therapeutics.